X4 Pharmaceuticals, Inc XFOR

About X4 Pharmaceuticals, Inc (XFOR): stock profile, AI score and financials

X4 Pharmaceuticals, Inc (XFOR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XFOR at 28.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,540 of 2,925 stocks — the bottom half of the AI-ranked universe. XFOR scores in the top quartile across revenue growth (99.4). Areas of concern include free cash flow (2.0) and revenue scale (2.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), X4 Pharmaceuticals, Inc reports quarterly revenue of $2.4M, net income of $-16.2M. Top institutional holders of XFOR by reported 13-F value include MORGAN STANLEY, FMR, Bain Capital Life Sciences Investors, based on the most recent SEC filings. XFOR trades on the Nasdaq exchange and files with the SEC under CIK 1501697. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XFOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for X4 Pharmaceuticals, Inc directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1501697 →